Space startup Varda raises $187 million in funding to make drugs in orbit

Space startup Varda has raised $187 million in Series C funding, bringing its total capital to $329 million, to accelerate its pioneering in-space drug manufacturing. The company, which leverages microgravity for novel drug crystallization and has successfully produced compounds like Ritonavir, plans to increase its flight cadence and expand lab operations. This substantial investment, led by Natural Capital and Shrug Capital with participation from notable investors, underscores growing confidence in the commercial viability of orbital manufacturing and positions Varda as a key player in the emerging space-based economy.

Analysis

Varda Space Industries has secured $187 million in a Series C funding round, elevating its total capital raised to $329 million and signaling strong investor confidence from prominent firms like Natural Capital, Peter Thiel, and Lux Capital. This capital infusion is earmarked to scale its core mission: in-space pharmaceutical manufacturing, a process validated by the successful creation and FAA-approved return of the drug Ritonavir. The company is demonstrating tangible operational momentum, with three successful launches completed, a fourth mission currently in orbit, and a fifth anticipated by year-end. This progress is underpinned by a key strategic partnership with the publicly-traded Rocket Lab (RKLB), which supplies the Photon spacecraft for Varda's missions. Furthermore, Varda is diversifying its technological application by operating a testbed for the U.S. government to advance reentry vehicle technology, suggesting a potential defense and infrastructure revenue stream. The expansion of its physical footprint with a new lab in California and operations in Alaska indicates a strategic shift from research and development towards increasing production cadence for more complex molecules, positioning Varda as a commercial frontrunner in the nascent orbital economy.

Key Decisions for Investors

• For investors in Rocket Lab (RKLB), Varda's accelerated funding and flight schedule represents a positive validation of RKLB's Photon spacecraft platform and could signal a growing revenue stream from the commercial space sector.
• The significant capital flow into Varda signals the growing viability of in-space manufacturing, prompting investors to monitor this nascent sector for long-term disruptive potential in both the pharmaceutical and aerospace industries.
• Given Varda's successful proof-of-concept with Ritonavir and its U.S. government contract, investors should watch for key milestones, such as the return of its fourth capsule and progress on more complex molecules, as catalysts for the valuation of the broader orbital manufacturing ecosystem.